This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-14 and is reviewed periodically as new material appears.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
=== Physical properties === Compared to hydrogen in its natural composition on Earth, pure deuterium (2H2) has a higher melting point (18.72 K vs. 13.99 K), a higher boiling point (23.64 vs. 20.27 K), a higher critical temperature (38.3 vs. 32.94 K) and a higher critical pressure (1.6496 vs. 1.2858 MPa). The physical properties of deuterium compounds can exhibit significant kinetic isotope effects and other physical and chemical property differences from the protium analogs. 2H2O, for example, is more viscous than normal H2O. There are differences in bond energy and length for compounds of heavy hydrogen isotopes compared to protium, which are larger than the isotopic differences in any other element. Bonds involving deuterium and tritium are somewhat stronger than the corresponding bonds in protium, and these differences are enough to cause significant changes in biological reactions. Pharmaceutical firms are interested in the fact that 2H is harder to remove from carbon than 1H. Deuterium can replace 1H in water molecules to form heavy water (2H2O), which is about 10.6% denser than normal water (so that ice made from it sinks in normal water). Heavy water is slightly toxic in eukaryotic animals, with 25% substitution of the body water causing cell division problems and sterility, and 50% substitution causing death by cytotoxic syndrome (bone marrow failure and gastrointestinal lining failure). Prokaryotic organisms, however, can survive and grow in pure heavy water, though they develop slowly.
=== Age-related macular degeneration === In 2015, a retrospective analysis comparing the incidence of age-related macular degeneration (AMD) between patients taking versus not taking levodopa found that the drug delayed onset of AMD by around 8 years. The authors state that significant effects were obtained for both dry and wet AMD.
Adrenocorticotropic hormone release is triggered by corticotropin-releasing hormone and inhibited by rising glucocorticoid levels. The gonadotropins—follicle-stimulating hormone and luteinizing hormone regulate the functions of the gonads in both sexes. Follicle-stimulating hormone stimulates sex cell production; luteinizing hormone stimulates gonadal hormone production. Gonadotropin levels rise in response to gonadotropin-releasing hormone. Negative feedback of gonadal hormones inhibits gonadotropin release. Prolactin promotes milk production in human females. Its secretion is prompted by prolactin-releasing hormone and inhibited by prolactin-inhibiting hormone. The intermediate lobe of the pituitary gland secretes only one enzyme that is melanocyte stimulating hormone. It is linked with the formation of the black pigment in our skin called melanin. The neurohypophysis stores and releases two hypothalamic hormones:
Systemic diseases may be associated with the development of periodontitis. It is thought that the host immune response to plaque is altered by the systemic condition. Hematological disorders associated with periodontitis include acquired neutropenia, leukemias and others. Genetic disorders potentially associated include familial and cyclic neutropenia, Down syndrome, leukocyte adhesion deficiency syndromes, Papillon–Lefèvre syndrome, Chédiak–Higashi syndrome, histiocytosis syndromes, glycogen storage disease, infantile genetic agranulocytosis, Cohen syndrome, Ehlers–Danlos syndrome (Types IV and VIII), hypophosphatasia, and others.
=== Oxoacids, oxoanions, and oxoacid salts === Many nitrogen oxoacids are known, though most of them are unstable as pure compounds and are known only as aqueous solutions or as salts. Hyponitrous acid (H2N2O2) is a weak diprotic acid with the structure HON=NOH (pKa1 6.9, pKa2 11.6). Acidic solutions are quite stable but above pH 4 base-catalysed decomposition occurs via [HONNO]− to nitrous oxide and the hydroxide anion. Hyponitrites (involving the N2O2−2 anion) are stable to reducing agents and more commonly act as reducing agents themselves. They are an intermediate step in the oxidation of ammonia to nitrite, which occurs in the nitrogen cycle. Hyponitrite can act as a bridging or chelating bidentate ligand. Nitrous acid (HNO2) is not known as a pure compound, but is a common component in gaseous equilibria and is an important aqueous reagent: its aqueous solutions may be made from acidifying cool aqueous nitrite (NO−2, bent) solutions, although already at room temperature disproportionation to nitrate and nitric oxide is significant. It is a weak acid with pKa 3.35 at 18 °C. They may be titrimetrically analysed by their oxidation to nitrate by permanganate. They are readily reduced to nitrous oxide and nitric oxide by sulfur dioxide, to hyponitrous acid with tin(II), and to ammonia with hydrogen sulfide. Salts of hydrazinium N2H+5 react with nitrous acid to produce azides which further react to give nitrous oxide and nitrogen.
Sources: en.wikipedia.org
On July 5, 1932, to honor the memory of the recently deceased Dr. Llansó, the name was changed again to the Hogar Nacional Masónico Llansó (English: Llansó National Masonic Retirement Home), and its mission was changed from being a homeless shelter to that of a retirement home and hospice for the elderly.
Dog saliva has been said by many cultures to have curative powers in people. "Langue de chien, langue de médecin" is a French saying meaning "A dog's tongue is a doctor's tongue", and a Latin quote that "Lingua canis dum lingit vulnus curat" or "A dog's saliva can heal your wound" appears in a thirteenth-century manuscript. In Ancient Greece, dogs at the shrine of Aesculapius were trained to lick patients, and snake saliva was also applied to wounds. Saint Roch in the Middle Ages was said to have been cured of a plague of sores by licking from his dog. The Assyrian Queen Semiramis is supposed to have attempted to resurrect the slain Armenian king Ara the Beautiful by having the dog god Aralez lick his wounds. In the Scottish Highlands in the nineteenth century, dog saliva was believed to be effective for treating wounds and sores. In the Gospel of Luke (16:19-31), Lazarus the Beggar's sores are licked by dogs, although no curative effects are reported by the Evangelist.
==== Pharmacokinetics ==== Nabiximol is rapidly absorbed from the buccal mucosa (membranes inside the mouth). It is then widely distributed in different body tissues, especially fatty tissues due to its high lipophilicity. Thus, it may be stored in the fatty tissues for as long as four weeks, which then slowly release back into the blood stream. THC and CBD, the two components of nabiximol is mainly metabolised in the liver via CYP450 enzymes (2C9, 2C19, 2D6 and 3A4) to 11-hydroxy-tetrahydrocannabinol and 7-hydroxy-cannabidiol respectively. Excretion is primarily in faeces.
=== Board positions === As of 2024, Bhatt serves on the Board of Directors and Science and Technology Committee of Bristol Myers Squibb. He is on the cardiovascular advisory board for McKinsey and is a consultant to Broadview Ventures. He had previously served on the Board of Directors of the Boston VA Research Institute and as a Trustee of the American College of Cardiology. He is President of the Board of Directors of the American Heart Association New York City chapter.
=== Non-denaturing-condition electrophoresis === A non-denaturing electrophoretic procedure for isolating bioactive metalloproteins in complex protein mixtures is preparative native PAGE. The intactness or the structural integrity of the isolated protein must be confirmed by an independent method.
Sources: en.wikipedia.org
Structural alignment attempts to establish homology between two or more polymer structures based on their shape and three-dimensional conformation. This process is usually applied to protein tertiary structures but can also be used for large RNA molecules. In contrast to simple structural superposition, where at least some equivalent residues of the two structures are known, structural alignment requires no a priori knowledge of equivalent positions. Structural alignment is a valuable tool for the comparison of proteins with low sequence similarity, where evolutionary relationships between proteins cannot be easily detected by standard sequence alignment techniques. Structural alignment can therefore be used to infer evolutionary relationships between proteins that share very little common sequence. Those relationships can then be characterized through structural phylogenetics. However, caution should be taken when interpreting any results as evidence for shared evolutionary ancestry due to the potential confounding effects of convergent evolution, by which unrelated or distantly-related amino acid sequences converge on a common tertiary structure. Structural alignments can compare two sequences or multiple sequences. Because these alignments rely on information about all the query sequences' three-dimensional conformations, the method can only be used on sequences where these structures are known. These are usually found by X-ray crystallography or NMR spectroscopy. It is possible to perform a structural alignment on structures produced by structure prediction methods.
== History == TMA-2 was first described in the scientific literature by Viktor Bruckner in 1933. Subsequently, Alexander Shulgin discovered the hallucinogenic effects of TMA-2 in 1962 and published them in 1964. The drug was later described in further detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
Proteins are not static objects, but rather populate ensembles of conformational states. Transitions between these states typically occur on nanoscales, and have been linked to functionally relevant phenomena such as allosteric signaling and enzyme catalysis. Protein dynamics and conformational changes allow proteins to function as nanoscale biological machines within cells, often in the form of multi-protein complexes. Examples include motor proteins, such as myosin, which is responsible for muscle contraction, kinesin, which moves cargo inside cells away from the nucleus along microtubules, and dynein, which moves cargo inside cells towards the nucleus and produces the axonemal beating of motile cilia and flagella. "[I]n effect, the [motile cilium] is a nanomachine composed of perhaps over 600 proteins in molecular complexes, many of which also function independently as nanomachines...Flexible linkers allow the mobile protein domains connected by them to recruit their binding partners and induce long-range allostery via protein domain dynamics. "
Malnutrition and being underweight are more common in the elderly than in adults of other ages. If elderly people are healthy and active, the aging process alone does not usually cause malnutrition. However, changes in body composition, organ functions, adequate energy intake and ability to eat or access food are associated with aging, and may contribute to malnutrition. Sadness or depression can play a role, causing changes in appetite, digestion, energy level, weight, and well-being. A study on the relationship between malnutrition and other conditions in the elderly found that malnutrition in the elderly can result from gastrointestinal and endocrine system disorders, loss of taste and smell, decreased appetite and inadequate dietary intake. Poor dental health, ill-fitting dentures, or chewing and swallowing problems can make eating difficult. As a result of these factors, malnutrition is seen to develop more easily in the elderly. Rates of malnutrition tend to increase with age with less than 10 percent of the "young" elderly (up to age 75) malnourished, while 30 to 65 percent of the elderly in home care, long-term care facilities, or acute hospitals are malnourished. Many elderly people require assistance in eating, which may contribute to malnutrition. However, the mortality rate due to undernourishment may be reduced. Because of this, one of the main requirements of elderly care is to provide an adequate diet and all essential nutrients. Providing the different nutrients such as protein and energy keeps even small but consistent weight gain.
Lettres à ses amis et quelques autres, Édition de Joseph Brami et de Michèle Sarde avec la collaboration d’Élyane Dezon-Jones, Paris, Gallimard, 1995, 736 p. ISBN 2070738574. D’Hadrien à Zénon, Correspondance 1951-1956 de Marguerite Yourcenar. Texte établi et annoté par Colette Gaudin et Rémy Poignault avec la collaboration de Joseph Brami et Maurice Delcroix; édition coordonnée par Élyane Dezon-Jones et Michèle Sarde; préface de Josyane Savigneau, Paris, Gallimard, 2004, 640 p., ISBN 207075684X. « Une volonté sans fléchissement ». Correspondance 1957-1960, texte établi, annoté et préfacé par Joseph Brami, Maurice Delcroix, édition coordonnée par Colette Gaudin et Rémy Poignault avec la collaboration de Michèle Sarde, Paris, Gallimard, 2007, 549 p. Marguerite Yourcenar, Silvia Baron Supervielle, Une reconstitution passionnelle. Correspondance 1980-1987, édition établie, annotée et commentée par Achmy Halley, Avant-propos de Silvia Baron Supervielle, Paris, Gallimard, 2009, 99 p. « Persévérer dans l’être ». Correspondance 1961-1963 (D’Hadrien à Zénon, III), texte établi et annoté par Joseph Brami et Rémy Poignault, avec la collaboration de Maurice Delcroix, Colette Gaudin et Michèle Sarde, préface de Joseph Brami et Michèle Sarde, Paris, Gallimard, 2011, 503 p. « En 1939, L’Amérique commence à Bordeaux ». Lettres à Emmanuel Boudot-Lamotte (1938-1980), édition établie, présentée et annotée par Élyane DEZON-JONES et Michèle SARDE, Paris, Gallimard, 2016, 304 p. « Le pendant des Mémoires d’Hadrien et leur entier contraire ».
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.